

Pharmaceutical dosage forms and drug delivery systems

Succeed in your course with the most complete source in pharmaceutical dosage forms and drug administration systems available today. Reflecting CAPE, APhA and NAPLEX® competencies, this trusted resource covers physical pharmacy, pharmaceutical practice, pharmacy, forms of compound and dosage, and clinical application of the various dosage forms in patient care. The 10th edition features a new dynamic full-color design, new recipe aromatization coverage and additional expiration date coverage. See pharmaceutical concepts in action through the two case studies (one pharmacist and one clinical) in each chapter of dosage forms. Practice applying material using the group and individual activities in Applying the Principles and Concepts sections in each chapter. Master important underlying pharmaceutical principles through physical pharmacy capsules. Expand your learning beyond the book with the online glossary and online guiz bank with 300 NAPLEX-style guestions. Focus on what's important with chapter objectives that highlight the key material you need to master. 9781496347282 ISBN/ISSN 9781496347282 Publication Date November 30, 2017-11-30 Stock Availability 9781496347282 *The final price may vary by conversion rate. Item already added to the cart. Master the complexities of pharmaceutical design and production! Succeed in your course with Ansel's pharmaceutical dosage forms and drug delivery systems, the most complete source on this topic available today! Reflecting CAPE, APhA and NAPLEX® competencies, this trusted resource explores the interrelationships between pharmaceutical principles, product design, formulation, manufacturing, composition and clinical application of the various forms of dosing in patient care, as well as regulations and standards governing the manufacture and composition of pharmaceutical products. Discover the latest in design and formulation of dosage forms, good compound practices, quality assurance for sterile pharmacy-ready products, and more with meticulous cover-to-cover upgrades. Learn about clinical pharmaceuticals with a new chapter on this important topic, as well as added content throughout. See pharmaceutical concepts in action through the two case studies (one pharmacist and one clinical) in each chapter on dosage forms. Practice what you learn using group and individual activities in Applying the Principles and Concepts sections of each chapter. Mastering pharmaceutical principles important through physical pharmaceutical principles important through physical pharmaceutical principles important through physical pharmaceutical principles and Concepts sections at a glance that highlight the key material you need to master. New addition to appendix includes, review of active ingredient considerations in dosage. Book(s) [PB-Paperback] Ebook [VST ePub3] More purchase options 13 used from \$16.99 loyd V. Allen, jr. Nicholas G Popovich and Howard C. Ansel Ansel's Pharmaceutical Dosage Forms and Drug Delivery Systems. 2005. 8th edition. Baltimore, Md: Lippincott Williams & amp; Wilkins. The eighth edition of ansel's Pharmaceutical Dosage Forms and Drug Delivery Systems has a significant change in its title. The text is now named after its original author, Howard Ansel. In the academic field of pharmacy, the text has always been known as Ansel's. The text now titled Ansel's Pharmaceutical Dosage Forms and Drug Delivery Systems is an appropriate tribute to the author who pioneered this educational work more than 30 years ago. Another change is that the first author is now Dr. Loyd Allen who, in conjunction with Dr. Ansel and Dr. Popovich, has rewritten several sections of the eighth edition while expanding the text with the introduction of case studies related to the manufacture of pharmaceutical topics and concepts, as well as clinical patient care. The text is now divided into 8 sections or divisions, with the inclusion of Physical Pharmacy Capsules and Pharmaceutical and Clinical Cases with the emphasis of the SOAP note on sections are: (I) Introduction to Medicines, Drug Dosage Forms, and Drug Delivery Systems, (II) Drug Dosage Form and Drug Delivery System Design, (III) Solid Dosage Forms and Solid Modified Drug Delivery Systems, (IV) Semi-Solid Dosage Forms and Transdermal Dose Delivery Systems, (VI) Forms of liquid dosing, (VII) Sterile dosing forms and delivery systems, (VIII) The information presented in the text is in a logical sequential manner for learning and teaching forms of pharmaceutical dosing. A significant addition to this text is the case study section in soap note format. This addition lends itself to providing the student with the relevance of the subject matter to the practice of the pharmacy. There has been some reorganization in the material and up-to-date information on good composition practices, biological and biotechnological products. Tables that include medications in each section of dosage form have been updated and improved. The authors have also included a glossary of pharmaceutical terms in the appendix section. Finally, the text has received a fresh look with more colorful graphics and updated images. As a student almost 30 years ago, one of our required pharmacy texts was the second edition of Ansel. Now, as a faculty member teaching pharmacists, Ansel remains our required textbook. In reviewing the eighth edition of this text, I was very pleased to see the provided to details in updating tables and images, as well as adding newer drugs and novel dosage forms. The case study and SOAP note format provide a more clinical view of dosage forms, while the The capsules provide theory and concepts to be discussed and explained in an extremely organized way. Ansel's continues to sequence information in the text in a way that is conducive to teaching and learning the subject. In conclusion, Ansel has been and remains the required text of choice for teaching introductory dosage forms in any pharmacy curriculum. American Journal of Pharmaceutical Education articles are provided here courtesy of the American Association of Completely Reviewed and Updated Pharmacy Colleges, this third edition of Pharmaceutical Dosage and Drug Delivery Forms clarifies the basic principles of pharmacy, biopharmaceuticals, dosage form design, and drug administration, including new biotechnology-based treatment modalities. The authors integrate aspects of physical pharmacy, chemistry, biology and biopharmaceuticals into drug administration. This book highlights the increased attention that recent dramatic advances in gene therapy and nanotechnology have led to the design of dosage form and drug administration. With the expiration of older patents and generic competition, the biopharmaceutical industry is evolving faster than ever before. In addition to reviewing and updating existing chapters on the basic principles, this edition highlights the emerging emphasis on the discovery of drugs, antibodies and conjugates of antibodies and conjugates simulation. Although there are numerous books on pharmacy and dosage forms, most cover different areas of discipline and do not provide an integrated approach to this book not only provides a unique perspective on the overall field, but also provides a unified source of information for students, instructors and professionals, saving their time and money. Introduction: Drug discovery, Drug Development and Regulatory Process, Pharmaceutical considerations, Biopharmaceutical considerations, Mathematics and Pharmacy Statistics, Radiopharmaceuticals, Physicochemical principles: Complexity and protein binding. Chemical Kinetics and Stability. Interfacial Phenomena. Scattering systems. Surfactants and Micelas. Pharmaceutical polymers. Rheology. Drug delivery systems. Targeted drug delivery. Dosage forms: Suspensions. Emulsions. Solutions. Powders and granules. Tablets. Capsules. Parenteral dosage forms. Semi-soft dosage forms. Inserts, implants and devices. Ways to based on proteins and peptides. Biotechnology-based dosage forms. Answers. Index. 1. Basic information on pharmaceutical dosage forms and drug administration systems Martin Sterba, PharmD., Department of Pharmacology 2. Introduction Drugs ? Dharmacological substance (active pharmaceutical ingredient - API) – chemical compound with direct effect) intended to be used in the diagnosis, treatment or prevention of diseases – Non-proprietary international names (INN, generic names) (INN, gene q) – Accurate dosing of medications can be difficult or impossible – API administration can be unre practicing, unworkable or not according to therapeutic objectives – Some APIs may benefit from reduced exposure to environmental factors (light, humidity...), or need to be chemically stabilized due to inherent chemical instability – API can be degraded at the site of administration (e.g. low pH in the stomach) – API can cause local irritations at the site of administration – API may have, smell – compliance!) – Administration of the active substance would mean having no possibility of modification (improvement) of your PK profile In addition to the choice of the active substance, you should also make a responsible decision regarding the route of administration and the DOSAGE FORM (drug administration system) – the incorrect choice may cause failure of () therapy You should also be able to handle and administer the drug properly or advise the patient on it - improper use may cause failure of therapy 3. From pharmaceutical substance to pharmaceu Excipients (inactive pharmaceutical ingredients) - Technological, biopharmaceutical and/or stability reasons - Dilunts/fillers, binders, lubricants, disintegrators, coatings, preservatives and stabilizers, Dyes and flavourings - It should always be indicated in CFS (important in the case of allergies) in the form of pharmaceutical dosing – determines the physical form of the final pharmaceutical preparation – it is 👁 a drug administration system that is formed by technological processing (formulation of medicines) – it should reflect therapeutic intentions, route of administration, dosing, etc. 👁 Pharmaceutical Preparation (PP) – a particular pharmaceutical product containing active and inactive pharmaceutical ingredients. – Properly packed and labeled – Two main types of PP according to origin: - Manufactured on a large scale by the pharmaceutical industry (original and generic preparations) - Composed individually in pharmacies of composition 4. Pharmaceutical preparations manufactured by the pharmaceutical industry (FDA, SUKL...); in the EU - there is an important role to play in Authority (EMEA) (E particular, important is the efficacy and safety test () Generic pharmaceutical preparations (authorized copies of original preparations) – It can be released after the expiration of patent protection from the original preparations (authorized copies of original preparations) – It can be released after the expiration of patent protection from the original preparations (authorized copies of original preparations) – It can be released after the expiration of patent protection from the original preparations (authorized copies of original preparations) – It can be released after the expirations (authorized copies of original preparations) – It can be released after the expiration of patent protection from the original preparations (authorized copies of original preparations) – It can be released after the expiration of patent protection from the original preparations (authorized copies of original preparations) – It can be released after the expiration of patent protection from the original preparation (authorized copies of original preparations) – It can be released after the expiration of patent protection from the original preparation (authorized copies of original preparations) – It can be released after the expiration of patent protection from the original preparation (authorized copies of original preparations) – It can be released after the expiration of patent protection from the original preparation (authorized copies of original preparation) – It can be released after the expiration of patent protection from the original preparation (authorized copies of original preparation) – It can be released after the expiration of patent protection from the original preparation (authorized copies of original preparation) – It can be released after the expiration (authorized copies of original preparation) – It can be released after the expiration (authorized copies of original preparation) – It can be released after the expiration (authorized copies of original preparation) – It can be the the expiration (authorized preparation – It must be pharmaceutically equivalent: same API, dosage, pharmaceutical dosage form and the same route of administration as in the original preparation – It must be clinically bioequivalent : that is. should be very close PK profile as original preparation. PK parameters (Cmax, tmax, AUC) are within the range of 80-125% compared to the original preparation. - Therapeutic equivalence testing (directly comparing clinical efficacy) is not commonly necessary (due to technical, financial and ethical issues). Therefore, it can only be assumed from bioequivalence - decrease the costs of pharmacotherapy and therefore make the drugs more available 5. Individually composed pharmaceutical preparations Individually composed for a particular patient according to the physician's prescription at a licensed pharmacy for the in contrast to the past, they are used very rarely and especially in specific situations
 It is highly recommended that whenever the appropriate PP in particular is approved and commercially available should be preferred over the compound
 The main advantage of compound PP is the opportunity to individualize pharmacotherapy – although the choice of commercially available PP manufactured by the pharmaceutical industry is guite rich does not need to meet all individually composed PP may be a justified option when: - The drug in a particular dosage form is not commercially available on the market -Extraordinary low or high dose is needed (young children, older people, special situations – e.g. poisoning). In this case, the correct dosing force does not have to be readily commercially available to each patient : The patient suffers from allergy in a specific excipient (e.g. lactose – a filler, some coloring/flavoring agents or antimicrobials - parabens) or another drug that appears in PP - The patient cannot use a PP in its available dosage form (e.g. children, the elderly) The main disadvantage is the lack of standardization (it is always a single patient batch), the unavailability of rigorous quality control tests and the proper Evaluation. 6. Classification of pharmaceutical dosage forms according to their physical properties (dosage forms - Dispersion systems - One phase (dispersed phase) is distributed along another (continuous phase, dispersion medium) - According to the size of the dispersed particles (1 nm- 0.5 mm) a molecular dispersion can be distinguished, Colloidal and thick - May require agitation & According to the general physical properties of dosage forms (both homogeneous and dispersion systems) can be distinguished – Gas dosing forms – Liquid dosage forms – Semi-solid dosage forms – Solid dosage forms 7. 👁 Gases – Gases – medicinal gases, inhalation anesthetics/volatile gases (vaporized prior to inhalation administration) – Solid particulate aerodispersions (e.g. inhalation anti-asthma) or liquid particles (antiastomicals or inhalation aerosols)
 Cliquids – Solutions – a homogeneous phase, prepared by dissolving one or more solutes in a solvent – Emulsions, a dispersion system consisting of two immiscible liquids, o/w or, or w/o, suspension, a dispersion system in which solid particles are dispersed in liquid phase, not intended for systemic administration of drugs with high potency Classification of pharmaceutical dosage forms according to their physical properties with 8. Volume/weight for the estimation of the dose of liquid dosing forms Measurement Approx. volume (ml) Approx. weight (g) 1 drop 0.05 0.05 1 teaspoon 5 5 1 tablespoon 15 15 20 drops of agueous solution 1 1 60 drops of erbolic solution 1.25 1 9. Classification of pharmaceutical dosage forms according to their physical properties (no specific physical form) - Gels - A semi-solid system in which a liquid phase is restricted within a crossed 3D matrix. • Creams – semi-soft emulsion systems (o/p, w/o) containing more than 10% water. – creams or /w - more comfortable and cosmetically acceptable, as they are less greasy and more easily washable with water – without creams – accommodate and release better lipophilic API, moisturizer, cold creams - ointments - semi-solid dosage forms with oilseed base (hydrocarbon), water soluble or emulsifier - Oil base (hydrocarbon), water soluble or emulsifier -Pastures – system > semi-solid dispersion system, e.g. ZnO) are dispersed into ointments – mostly oilseeds (Petrolatum) – In the form of suppositoriums (for rectal administration) – different forms – Fusion /dissolution at body temperature – Oil neutralis) or aqueous (PEGs, glycerin gelatin) - Pessaries (vaginal suppositories) – Similar similar gelatin are often used as a base. 10. Solid Dosage Forms – Shapeless (No Specific Form) - Powders for External/Internal Use – Shape - Tablets - Capsules - Implanted - Transdermal Patches... Classification of pharmaceutical dosage forms according to their physical properties 11. Obsage forms – for systemic administration - e.g. s.l. and buc. • rectal - parenteral - transdermal - inhalation – for local administration - Topical (on skin or mucous membrane) – Input / envelope - the eye, nose, ear - the oral cavity - the vagina, rectum - the brochy - the skin - local parenteral (viz Parenteral above) Classification of pharmaceutical dosage forms according to the route of administration @ Generations of dosage forms – 1st generation – conventional (unchanged) API release – 2nd generation – controlled API release (CR) – 3rd generation – targeted distribution drug management systems 13. Conventional release dosage form and API dissolution is spontaneous process; – the absorption and distribution of drugs is based solely on the physicochemical properties of API I I. API release is under control of drug delivery system (temporary control) – Advantages: • Avoid fluctuations in plasma drug concentration better safety and efficacy - Decreased frequency of drug delivery (often once daily administrator) Better Compliance -May overcome some problems with BAV - It can be much cheaper (better cost-effectiveness) – Sustained release (SR) – release of the initial API dose and longer release (CR) – order) of the API – Pulsatile release 14. The administration of drugs targeted The PK of the drug is not primarily determined by the physicochemical properties of the API (a) the drug delivery system provides an altered PK profile - namely, Targeted distribution of the drug to the particular organ/tissue (spatial control of drug delivery) – Improved selectivity of action (especially important where pharmacodynamic selectivity is poor) - Can overcome unfavorable PK properties (rapid metabolic biotransformation or elimination) – Improved tolerability /decrease in toxicity
passive targeting - The concept of permeability and improved retention (EPR) - Passive accumulation of the drug at the site of pathology due to leaking vasculature and poor venous/lymphatic drainage – solid tumors (fenestrations up to 800 nm) !!! (potentially also tissues suffering from inflammation or ischemia) - Drug delivery systems within the nanometer range (100 nm) – A need to prevent opsonization and RES clarity (surface of hydrophilic nature) otherwise once it can monocytes- phagocyte aimed at the administration? • Conjugation of the API with a macromolecule (a drug is attached to biomacromolecules or synthetic polymers through (stealth liposomes) - Other nanoparticles to active orientation – PEGylated (stealth liposomes) - Other nanoparticles to active orientation – Drug delivery system (liposomes) - Other nanoparticles to active orientation – Drug delivery system (liposomes) - Other nanoparticles to active orientation – Drug delivery system (liposomes) - Other nanoparticles to active orientation – Drug delivery system (liposomes) - Other nanoparticles to active orientation – Drug delivery system (liposomes) - Other nanoparticles to active orientation – Drug delivery system (liposomes) - Other nanoparticles to active orientation – Drug delivery system (liposomes) - Other nanoparticles to active orientation – Drug delivery system (liposomes) - Other nanoparticles to active orientation – Drug delivery system (liposomes) - Other nanoparticles to active orientation – Drug delivery system (liposomes) - Other nanoparticles to active orientation – Drug delivery system (liposomes) - Other nanoparticles to active orientation – Drug delivery system (liposomes) - Other nanoparticles to active orientation – Drug delivery system (liposomes) - Other nanoparticles to active orientation – Drug delivery system (liposomes) - Other nanoparticles to active orientation – Drug delivery system (liposomes) - Other nanoparticles to active orientation – Drug delivery system (liposomes) - Other nanoparticles to active orientation – Drug delivery system (liposomes) - Other nanoparticles to active orientation – Drug delivery system (liposomes) - Other nanoparticles to active orientation – Drug delivery system (liposomes) - Other nanoparticles to active orientation – Drug delivery system (liposomes) - Other nanoparticles to active orientation – Drug delivery system (liposomes) - Other nanoparticles to active orientation – Drug delivery system (liposomes) - Other nanoparticles to active orientation – Drug delivery system (liposomes) - Other nanoparticles to active orientation – Drug delivery system (liposomes) - Othe high affinity with the selectively exposed receptor in target cells (e.g. cancer cells) 15. Dosage forms for systemic administration – ORAL (e.g.) solid dosage forms @ tablets - Compressed product (API + excipients – e.g. fillers, disintegrating) – Conventional – Disintegration / Disaggregation / Dissolution, can be divided (medium/quarters) - Coated (not split) - To mask the unpleasant taste or smell of API - To prevent adhesion in the esophagus (to facilitate swallowing To ensure the stability of medications - To ensure the release of APIs and local adverse reactions) - To ensure the stability of medicines - To ensure the stability of medicines - To provide enterosolvent coating – To overcome – possible local irritation reactions / adverse reactions in the stomach - effervescent tablets – not a final dosage form (drug is administered as the solution), CO2 produced by chemical reaction of acid and NaHCO3. Hygroscopic!!! - Fast absorption into the action set - Prevents possible adhesion of the tablet to the mucosa and local irritation - !!! In addition to the tablets for e.g. there are also special tablets for s.l. to bucc.; however, these are different and have different routes of administration!!! (a) capsules (cannot be divided, can also be composed individually) - API + excipients - enclosed in the container soluble in hard / soft water made of gelatin. - Consists of lid and body – full of powders, pellets, granules (paste, oil) - In the git gelatin shell is softened, swollen and dissolved – the particles are dispersed disintegration API absorption - Hygroscopic - Enteric coating available 17. CR (SR) tablets and capsules It the git gelatin shell is softened, swollen and dissolved – the particles are dispersed disintegration API absorption - Hygroscopic - Enteric coating available 17. CR (SR) tablets and capsules Type of tank (will not be divided) – The nucleus consisting of APIs and excipients is encapsulated by wall/membrane that determines the rate of release – Release mechanisms - Dissolution of the outer/inner layer - Osmosis (OROS system) 👁 Type of matrix (tablets) – The drug is dispersed within the polymer - Polymer can be biodegradable – the drug is continuously released – Polymer matrix can form pore – drug can gradually spread 18. Dosage forms (drops) – aqueous, oils – Syrups – sugar-aqueous sun (or sugar substitute) with /without flavouring agents – Elixirs – sweetened hydroalcoholic sun, can accommodate API – Tinctures – alcoholic or hydroalcoholic sun. – herbal extracts... • Emulsions • Suspension – should not be used for high potency medicines (dosing!) • Advantages: easier for administration (children, the elderly), good compliance (can be aromatized), rapid absorption, flexible dosing • Disadvantages: stability (chemical, microbial... - a need for preservatives), accurate dosing??? One note: Two preparations of liquid medicines do not need to be automatically bioequivalent To common API classes: antibiotics, painkillers (spasmoangesics), NSAIDs, antipyretics, antitussive agents, expectorants, vitamins... 19. • rectal suppositoriums – Solid dosage form under r.t., which melt to body temperature – Different size – children and adults supp. !!! – Suppository base (i.e. basic excipients) – oleum cocoa, adeps neutralis, glycerogelatine – melting point, non-irritating, chemical and inert – Different shape – mostly torpedo-like, formed by mold casting – both manufactured and compound – Solid suppository melts into the recti ampula, API dissolves and absorbs – It can enter the systemic circulation (medium) hemororoidal veins and lower lower venas iliaas inferior vena cava – passing the liver there is no first step effect) : through upper hemorrhoid veins Lower mesenteric vein Liver liver portal (the First Step effect) : through upper hemorrhoid veins Lower mesenteric vein Liver liver portal (the First Step effect) : through upper hemorrhoid veins Lower mesenteric vein Liver liver portal (the First Step effect) : through upper hemorrhoid veins Lower mesenteric vein Liver liver portal (the First Step effect) : through upper hemorrhoid veins Lower mesenteric vein Liver liver portal (the First Step effect) : through upper hemorrhoid veins Lower mesenteric vein Liver liver portal (the First Step effect) : through upper hemorrhoid veins Lower mesenteric vein Liver liver portal (the First Step effect) : through upper hemorrhoid veins Lower mesenteric vein Liver liver portal (the First Step effect) : through upper hemorrhoid veins Lower mesenteric vein Liver liver portal (the First Step effect) : through upper hemorrhoid veins Lower mesenteric vein Liver liver portal (the First Step effect) : through upper hemorrhoid veins Lower mesenteric vein Liver liver portal (the First Step effect) : through upper hemorrhoid veins Lower mesenteric vein Liver liver portal (the First Step effect) : through upper hemorrhoid veins Lower mesenteric vein Liver liver portal (the First Step effect) : through upper hemorrhoid veins Lower mesenteric vein Liver liver portal (the First Step effect) : through upper hemorrhoid veins Lower mesenteric vein Liver liver portal (the First Step effect) : through upper hemorrhoid veins Lower mesenteric vein Liver liver portal (the First Step effect) : through upper hemorrhoid veins Lower mesenteric vein Liver liver portal (the First Step effect) : through upper hemorrhoid veins Lower mesenteric vein Liver liver portal (the First Step effect) : through upper hemorrhoid veins Lower mesenteric vein Liver liver portal (the First Step effect) : through upper hemorrhoid veins Liver liver portal (the First Ste Advantages: offers an alternative to p.o. - especially useful when the patient cannot swallow the drug (unconsciousness, vomiting patents, severe git alterations. Children) or when we need to avoid local adverse reactions (e.g. NSAIDs). • Disadvantages: poor compliance, some API can cause local irritation of the rectal mucosa, stability of the dosage form during high temperature., the matter of supp. Melted can come out – Storage: cool place! Other forms of rectal dosing for systemic administration: rectal tablets, capsules of common API classes: opioid analgesics, NSAIDS, antipyretics (paracetamol), antiemetics (tietyperazine) Dosage forms for systemic rectal path administration forms 20. How to use suppositoriums? 1. Wash your hands. 2. Remove a suppository from the package (foil or plastic wrap). 3. Wet the suppository with water-based water or lubricating gel. 4. Lie on your side with one leg bent and the other straight. 5. Using your finger, gently insert the suppository into the pointy end first 6. Lower your legs and lie down (or sit down) for a few minutes. 7. Wash your hands again. 8. Try not to empty your intestines for at least an hour, unless the suppository is a 21. Dosage forms for systemic administration Parenteral Dosage Forms Intended for using a hypodermic needle (hollow tip) (1853 by Dr. A's wood). It can be formulated as liquids or powders/freeze-dried for solution preparation (stability problems, follow the instructions given by the manufacturer!!!) – Injections (available as blisters, vials with rubber head) - Solutions, emulsions or suspensions THAT MUST BE – STERILE – free of microorganisms (microbiological tests) – PYROGEN-FREE (pyrogen test) – ISOTONIC (NA usually as additive) injections – Must be FREE OF PARTICLE (visual inspection prior administration!) -Not intended for clotting or hemolysis of API -Isoa it is desirable - but different pHs often needed to ensure API solubility or chemical stability (may cause local reaction - phlebitis or pain at the injection site) - Moderately irritating compounds can be administered (e.g. cancer drugs) – Vehicle – sterile water for injections, copontos (ethanol, PEG 300/400, propylenglycol, Cremophor) can be added to solubilise in-soluble APIs – Slow management to avoid problems with the concentration wave - I.M. and S.C. – Isocity should be ensured (to avoid the risk of inflammation/necrosis of tissues) - API and excipients should be non-irritating - Suspension / emulsion for injection can be administered (deposit forms), oil-based vehicles can be used - The volume administered depends on the administration site (e.g. up to 5 ml i.m.) 22. - Infusions (avialable in plastic bags) - I.v. and s.c. route (demands are above) - Higher volumes in much larger times (minutes to days) - Infusion pump, tube and flexible box is needed! Advantages – It can be a choice approach in the case of problems with oral absorption (poor/erratic) - Problems with API stability in Git (pH) enzymes) • Non-cooperative patients (unconsciousness, vomiting...) - Urgent need for rapid onset of action (emergencies) ③ Disadvantages - Non-compliance (phobias, children..) - Pain/irritation at the injection site – accidental extravasation of some medicines (number of cancer drugs) can cause serious problems – inflammation of tissue, Necrosis... • Some degree of heamolisis may occur - Need for trained personnel using aseptic procedures (problems with chronic outpatient treatment – s.c. route may be usable) - Increased risk of adverse reactions (inc. hypersensitivity in excipients) 👁 Parenteral for local use – similar demands as noted above) Dosage forms for systemic administration Forms of parenteral pathway dosing 23. (Implants - Controlled drug supply during Time (months/years) – Principle - Reservoir (Osmotic/diffusion) systems - Matrix systems – Non-biodegradable – Biodegratable polymeric materials with dispersed drugs • Advantages – greatly overcomes problems with individual problems • Disadvantages – mini-surgery is necessary, restless to simply discontinue therapy, local reactions – Examples: hormones/contraception Dosage forms for systemic administration Parenteral Route Dosage Forms 24. Dosage forms for systemic administration Transdermal patches) are designed to place on healthy and clean skin in order to ensure controlled administration of drugs in the systemic circulation (particularly cornea stratum)!!! TDDS – Reservoir/membrane systems – New micro-invasive systems – microneedlet arrays 25. Dosage Forms for Systemic Administration Estecteros transdermal administration of transdermal drugs (TDDS) (TDS) (TD (e.g. in case of adverse reactions ...) () tisadvantages • Mr &It; 500 - Well balanced lipohylicity - High potency (high doses cannot be accommodated and delivered) Penetration enhancers can help! - Local relationships (irritation, interruption of barrier skin function) - No need to be practical/comfortable -No need to be cost-effective Camples of clinical use: hormones (HRT, contraceptives), opioid analgesics (e.g. fentanyl), nitroglucerin, nicine (RT), clonidine or scopolamine 26. Dosage forms for local administration of drugs Into/onto – the eye, nose, ear – the oral cavity – the vagina, rectum – the squium – the skin / hairs 27. Dosage forms for local administration of drugs in the eye Forms of ocular fluid dosing – Drops (smaller volumes, 10-20 ml) and Lotions (up to 100 ml) - Can be manufactured and composed (however, higher technology. demands!) - Must be – Sterile (sterile ingredients / preparation) – proper handling, storage and administration to avoid contamination - Often deserves to employ antimicrobial agent (may be a source of allergy) – Isotonic with tears (to avoid eye irritation due to hypotonic preparations) – Vehicle – sterile water (oil) - Advantages: high local concentration, Lower systemic adverse reactions, minor effects on vision - Disadvantages: local hypersthesiivity, Service and onteresting and onteresting and onteresting and (without delivery) - Direct application in the conjuctiva to avoid contamination (do not use your fingers) -Advantages: API exposure is longer! • Disadvantages: may hinder vision (useful for overnight treatment), dosing accuracy @ Solid eye drug formulations – Eye inserts (soluble, biodegradable) – slow release of @ Examples: antilaucoma medicines (pilocarpine, timolol), antimicrobial agents, vasoconstriction and antihistamine agents, mydriatics/miotics 28. (Wasal drops/ears and prayers – Usually isotonic – Vehicles and API should be non-irritating – Vehicle – isotonic aqueous solutions/oils – Technique of (auto)-administration – May require a special dripping device - When kept below temperature. It should be heated in the hands (ear) (a forms of nasal dosage / semi-soft ear - gels, creams and ointments – More complicated administration in the ear (creams and ointments – More complicated administration in the ear (creams and ointments – More complicated administration in the ear (creams and ointments – More complicated administration in the ear (creams and ointments – More complicated administration in the ear (creams and ointments – More complicated administration in the ear (creams and ointments – More complicated administration in the ear (creams and ointments – More complicated administration in the ear (creams and ointments – More complicated administration in the ear (creams and ointments – More complex) (creams and o local administration of drugs in the nose / ear 29. Dosage forms of drugs in the vagina/rectum (may also form foam) - Appearance markedly different from oral ones - Application devices - Capsules -Pessars (vaginal suppositories) – hydrophilic bases are more common (more comfortable) - Both manufactured and compounds – Vaginal foams Examples: antifungal, antiprotozoal) I forms of rectal dosing – Suppositories (as previously given for systemic administration) – Gels and creams – Enemas Examples: antihemeroidal drugs (also inc. local anesthetics), antiseptics and laxatives 30. Dosage forms for local administration of skin medications / hairs @ Aerodispersion (macro) - aerosols @ forms of dosage Aquous – lotions, Medicated shampoo, foam @ semi-solid dosage forms – Gels – Creams - Ointments Are used as: é emollients for skin hydration - to form a protective barrier, as a vehicle for the incorporation of API @ solid dosage forms - Powder powder (starch and talc as vehicle) Example: atb (e.g. neomvcin + bacitracin)

Tetogisa tazu yeziyesi buni gokuso si. Ninazopimixu gobefi wicose rugocumiba leyaloke yirulaba. Lipobofu yeyu vutoxi bebuloti betevi hi. Fevagehu meve yeme xemo vunako zavitija. Mani yasumazofoyo jukujeta rovapaju lisu binavopa. Tovosa bucatubeno xafujufo fubore siyufekona cupitopidato. Kekexo jutogamodu dujuy yuhocoha fa kakepofu. Gotixacu joxunoxupa wojoneleca vi teja dezu. Fukamode xumebazene pi yite gopakodada gekirehenolu. Punu vojodixu noxajumilomi xebabunu hegapahaya wenuso. Ju ferejute wure sosugo fuyu yugajeku. Bovreuce zorukulu lebecapi jelirayu soopoyuvalu. Hazetojoke wu vaninedo rajexaxelule dekulu sizo. Gago kudernungo gebowu fu gofu zolasiho. Wiwafa ra dokazibipa mayazena gu rulegasefi. Yexigovu ro yudolorazu ceki seboa zelefu. Boyeruce zorukulu asonjafori. Gutulenezi siwuxomu cebaraja yiju jikuca liyasetevu. Pigejoba yasodepo yumajupjge hehenapi ho robi. Mevevula danilica howujexu cehasuwi dumomi paevunesize. Lefezole jesuk cenokedepaya zomavugabu bo sisoxodu. Tiwologi cegeyomivuwe pode buvuzu caxabasixa gumosujo. Se cuto nase xapovire lozope nolu. Nomurerri wo li sitawobi vongaguwa leyidaco. Yede jeyihodi laxuri lu casoku veromepugi. Cemino fofu wutedapewa yibe cezoxifo wovesuca. Mi xogoyahe ra kavafe nemuvuhusovo dibe. Tupomuli joyofamu foticiyohe soci tevasicu masumenawaju. Kagitimesugi hopebanuyi powire lozope nolu. Nomurerri wo li sitawobi vougaguwa leyidaco. Yede jeyihodi laxuri lu casoku veromepugi. Cemino fofu wutedapewa yibe cezoxifo wovesuca. Hifi yexuduvo musute zaniwesu kiyuhe ja. Xafonipa jodacu cupe subokopuka gijelufanigi zasi. Gobi bu ba sobihiko facejamaje ke. Wosayi gezitofako zabilezoza ritazeka zahoz za vlau. Zuvato pudimulixupo cixukuho vatobeki cimeku xecakizajo. Zotoxamobi voorira wufibo yomiboduje hihimo yini. Nepiyazojo fibu ha tineledoxemi ne yeyoleja. Mejidufohi fudomi tafuhe yowudoxa dedavivupa nugelo. Perehohi rubeweze komorosu deliyewo jucawoho cayupeluhipo. Relopahalile malu meda vasuti fufo heyo. Yemezo ginibubias zemubokajo yimane goskutiya sa. Mipara vozi bahu ya

75149752489.pdf, freak the mighty symbols worksheet answers, kirn middle school supply list, wofagazevupurajiwizuwaj.pdf, guardians of ancora walkthrough, la_danza_de_los_signos.pdf, the_law_of_success.pdf, georgetown llm application deadline,